Caffeine Versus Placebo for Spinal Headaches

This study has been completed.
Sponsor:
Information provided by:
United States Naval Medical Center, Portsmouth
ClinicalTrials.gov Identifier:
NCT00809627
First received: December 16, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

December 16, 2008
December 16, 2008
January 2007
May 2008   (final data collection date for primary outcome measure)
Pain as measured by Visual Analog Scale [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Caffeine Versus Placebo for Spinal Headaches
A Prospective Trial of IV Caffeine vs Placebo for Post-Dural-Puncture Headache in the Emergency Department

Caffeine will be studied against placebo in patients with positional headache after a lumbar puncture (aka "spinal headache").

Pain will be assessed at set intervals using a Visual Analog Scale. Blood patch therapy will be offered to all those still in pain at the end of one hour after drug administration.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Post Dural Puncture Headache
  • Drug: Caffeine
    Caffeine 500 mg IV
    Other Name: Treatment group
  • Drug: saline
    Normal saline
    Other Name: Placebo control group
  • Experimental: 1
    IV caffeine with saline and opiate
    Intervention: Drug: Caffeine
  • Placebo Comparator: 2
    IV saline with opiate
    Intervention: Drug: saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • diagnosed with post dural puncture headache

Exclusion Criteria:

  • age < 18
  • pregnant
  • allergic to caffeine
  • cardiac or peripheral vascular disease
  • uncontrolled hypertension
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00809627
CIP 2006 0051
Yes
Mark Kostic, MD, Naval Medical Center Portsmouth
United States Naval Medical Center, Portsmouth
Not Provided
Study Chair: Mark A Kostic, MD United States Naval Medical Center, Portsmouth
Principal Investigator: Marcelo Darabos, MD United States Naval Medical Center, Portsmouth
United States Naval Medical Center, Portsmouth
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP